Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib versus lapatinib + capecitabine in HER2-positive advanced or metastatic breast cancer
2008-005425-11Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Neratinib monotherapy with Lapatinib + capecitabine (2 arms). Primary endpoint: Progression-free survival. Started Nov 2008; status: completed.
02
Drugs
neratiniblapatinibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-005425-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005425-11.